Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CPG 7909 Injection, PF-03512676
CPG 7909 · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| CPG 7909 Injection plus chemotherapy | EXPERIMENTAL | CPG 7909 Injection plus DTIC |
| Chemotherapy alone | ACTIVE_COMPARATOR | dacarbazine |
| CPG 7909 Injection 10 mg | EXPERIMENTAL | - |
| CPG 7909 Injection 40 mg | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection |
| 2 | ACTIVE_COMPARATOR | Chemotherapy (a taxane and a platinum compound) |
| CPG 7909 Injection | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | 0.01 mg/kg CPG 7909 plus Herceptin® |
| Cohort 2 | EXPERIMENTAL | 0.04 mg/kg CPG 7909 plus Herceptin® |
| Cohort 3 | EXPERIMENTAL | 0.16 mg/kg CPG 7909 plus Herceptin® |
| Cohort 4 | EXPERIMENTAL | 0.32 mg/kg CPG 7909 plus Herceptin® |
| Name | Type | Description |
|---|---|---|
| CPG 7909 Injection | DRUG | CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly. |
| dacarbazine | DRUG | dacarbazine 850mg/m2 in three-week cycles until disease progression |
| Chemotherapy | DRUG | Chemotherapy in three-week cycles until disease progression: dacarbazine 850mg/m2 |
| CPG 7909 | DRUG | CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle. |
| Herceptin® | DRUG | Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert |
Inclusion Criteria: * Histologically or cytologically confirmed melanoma that is metastatic. * Measurable disease according to the RECIST criteria. * Karnofsky Performance Status of \> 70. Exclusion Criteria: * Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metasta...
CPG 7909 is an investigational oncology drug developed by Pfizer, Inc. (ticker: PFE). It has been studied in several cancer types, including melanoma, metastatic breast cancer, non-small cell lung cancer, and renal cell carcinoma. It is also known as CPG 7909 Injection.
CPG 7909 has been studied for the treatment of several cancers: melanoma, metastatic breast cancer, non-small cell lung cancer, and renal cell carcinoma. These are the indications explored in its clinical trials. It is not described as approved for any indication.
CPG 7909 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development of CPG 7909 Injection across the studied cancer indications.
CPG 7909 is in Phase 2 development. Its clinical program includes Phase 2 trials in melanoma and non-small cell lung cancer, along with Phase 1 trials in renal cell carcinoma and metastatic breast cancer. All listed trials are completed.
CPG 7909 has been evaluated in completed trials including NCT00070642 in melanoma, NCT00070629 in non-small cell lung cancer, NCT00043407 in stage IV renal cell cancer, and NCT00031278 in metastatic breast cancer. These studies are completed, and no trials are currently active.
Yes, CPG 7909 Injection is another name for CPG 7909. The two names refer to the same investigational oncology drug developed by Pfizer, Inc. (ticker: PFE).